A generation ago, a big clot in the brain meant paralysis or worse. Today, doctors can diagnose clots on AI-enabled brain scans; provide life-saving, targeted medications; or snake a catheter from a patient’s groin into the brain to vacuum out the clot. If they intervene in time, they can watch speech and movement return before the sedatives wear off. How did that happen—and what’s still missing?

In this episode of From Our Neurons to Yours, Stanford neuroscientist and neurocritical care specialist Marion Buckwalter, MD, PhD retraces the 70-year chain of curiosity-driven research—biochemistry, imaging, materials science, AI—behind today’s remarkable improvements in stroke care. She also warns what future breakthroughs are at stake if support for basic science stalls.

Learn More

Buckwalter Lab site

History of Stroke Care:

• Tissue Plasminogen Activator for Acute Ischemic Stroke (NINDS) On the development of the first-gen clot-busting drug, tPA 
• Optimizing endovascular therapy for ischemic stroke (NINDS) On the development of mechanical clot clearance using thrombectomy.
• Mechanical Thrombectomy for Large Ischemic Stroke (Neurology, 2023) A literature meta-analysis shows that thrombectomy improves stroke outcomes by 2.5X, on top of 2X improvements from clot-busting drugs

The uncertain future of federal support for science

• The Gutting of America’s Medical Research: Here Is Every Canceled or Delayed N.I.H. Grant (New York Times, 2025)
• Trump Has Cut Science Funding to Its Lowest Level in Decades (New York Times, 2025)

We want to hear from your neurons! Email us at at [email protected] or... 

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

We want to hear from your neurons! Email us at at [email protected]

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.